相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois et al.
LANCET NEUROLOGY (2021)
Why Is Amyloid-beta PET Requested After Performing CSF Biomarkers?
Juhan Reimand et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
The implications of different approaches to define AT(N) in Alzheimer disease
Niklas Mattsson-Carlgren et al.
NEUROLOGY (2020)
Association of amyloid-beta CSF/PET discordance and tau load 5 years later
Juhan Reimand et al.
NEUROLOGY (2020)
Amyloid-β PET and CSF in an autopsy-confirmed cohort
Juhan Reimand et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
Arno de Wilde et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Sebastian Palmqvist et al.
EMBO MOLECULAR MEDICINE (2019)
Frontotemporal dementia is the leading cause of true A-/T plus profiles defined with Aβ42/40 ratio
Helene Pouclet-Courtemanche et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio
Eline Willemse et al.
ALZHEIMERS & DEMENTIA (2017)
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Sebastian Palmqvist et al.
BRAIN (2016)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice
Mathilde Sauvee et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
分享论文
